查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1250769

到 2028 年的眼科治療市場預測——按適應症、藥物類別、劑型、分銷渠道、最終用戶和地區進行的全球分析

Ophthalmic Disease Therapeutics Market Forecasts to 2028 - Global Analysis By Disease Indication, Drug Class, Dosage Form, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC，2022年全球眼科藥物市場規模將達到335.6億美元，2028年將以8.4%的複合年增長率增長，達到544億美元，預計將達到4000萬美元。

眼科藥物包括用於治療各種眼部疾病（例如青光眼、乾眼症和視網膜疾病）的藥物和藥物。 這些疾病在人群中日益流行，以及這些疾病造成的醫療保健負擔不斷增加，預計將增加對新藥和疾病管理方法的需求。

根據威爾士政府發布的 2021 年報告，威爾士的眼保健從業者人數從 2020 年 3 月的 885 人增加到 2021 年 3 月的 961 人。

市場動態

驅動程序

眼疾患病率上升

青光眼、視網膜疾病和乾眼症等眼病在人群中的患病率不斷上升，是全球患病率不斷上升的主要驅動因素之一。 各種眼病的患病率在老年人群中更高。 各種醫療保健組織、政府機構和市場進入者加大力度，提高了人群的診斷率和治療率。

約束

生物製劑成本高

生物製劑和生物仿製藥具有多種臨床益處，例如提高療效和提高安全性。 然而，也存在一些局限性，例如生物製劑的高成本和高自付費用。 由於生物製劑的諸多優點以及與其研究、開發和批准相關的各種成本，高成本是限制這些藥物在發展中國家使用的一個重要問題。

機會

創新藥物和療法的臨床試驗和候選管道數量增加

市場先驅和研究機構專注於開發創新療法並將其推向市場以治療疾病。 在預測期內，市場對眼科藥物的需求預計將增長，因為市場進入者專注於研發活動以開發治療這種疾病的新藥。 市場上主要競爭對手發現和推出新藥以滿足不斷增長的患者群體未滿足的需求的重點和活力預計會增加眼科藥物的消費。

威脅

認知度低

市場擴張受到嚴格的監管框架和模稜兩可的報銷做法的阻礙。 市場增長受到農村地區對各種眼部問題認識不足以及缺乏針對所有類型的人工晶狀體和隱形眼鏡的醫療保險的限制。 眼保健已經變得非常昂貴，全世界許多人無法獲得眼保健。 這被認為是全球眼藥市場增長放緩的主要原因。

COVID-19 的影響

在整個預測期內，COVID-19 對市場增長產生了負面影響。 大流行期間減緩市場增長的主要因素之一是骨科診所的臨時關閉以及醫療保健提供者對 COVID-19 患者的關注。 由於地方政府當局實施封鎖限制，許多眼科保健服務已被取消或推遲，患者到醫院和診所就診的次數也有所減少。 因此，全球患者對眼科藥物的需求下降。

預計抗 VEGF 區域在預測期內最大

由於需求和接受度的增加，以及擁有廣泛產品組合的強大市場參與者的存在，預計抗 VEGF 藥物將實現有利增長。 此外，該細分市場的增長歸功於 Avastin、LUCENTIS 等的卓越表現。 當前一類抗 VEGF 藥物有效但不持久，導致越來越多的參與者專注於開髮長效療法。

預計在預測期內，半固態部分的複合年增長率最高

由於軟膏、懸浮液和凝膠等產品的批准和上市不斷增加，預計半固體部分在預測期內將以最快的複合年增長率增長。 軟膏劑由於其在治療炎症性疾病、感染性疾病和乾眼症方面的高效性，其用途正在擴大，並且半固體產品的採用正在增加。 此外，各大公司對獲得批准和推出新產品的興趣日益濃厚，也有助於該領域的擴展。

市場份額最高的地區

由於各種眼病的患病率上升以及診斷和治療率的提高，預計亞太地區在預測期內將佔據最大的市場份額。 此外，該地區在眼科和眼保健方面不斷增加的支出，以及對一系列眼病的負擔得起的報銷，導致該地區主要國家的先進和新療法得到推廣。 眾多治療眼科疾病的創新藥物研發的有利環境和新藥審批的進展也是促進市場增長的因素。

複合年增長率最高的地區：

預計歐洲在預測期內的複合年增長率最高。 增加用於治療各種眼部疾病的生物製劑和生物仿製藥的上市，強調有效的眼部疾病管理，並擴大市場主要參與者的嘗試以擴大其地理足跡。 特別是，新產品的推出是對市場增長做出重大貢獻的少數幾個方面之一。 此外，政府投資的增加和醫療基礎設施的進步正在提振市場。

主要發展

2022年9月，Santen Pharmaceutical Co., Ltd.（以下簡稱“Santen Pharmaceutical Co., Ltd.”）與UBE聯合宣布“歐姆龍茶（Omidenpag異丙基滴眼液）0.002%”獲批用於原發性開角型青光眼或獲批被美國FDA批准為降低高眼壓症患者升高的眼內壓的適應症。

2022年6月，F. Hoffmann-La Roche（以下簡稱“F.HL”）獲得加拿大衛生部批准用於治療新生血管性年齡相關性黃斑變性（AMD）和糖尿病性黃斑水腫（Babismo獲批用於治療獲得了 DME)。

2022 年 3 月，Novartis公司的眼科藥物 Beovu 獲得歐盟委員會的批准，用於治療糖尿病性黃斑水腫引起的視力障礙。

2022 年 2 月，Viatris Inc. 獲得批准用於治療眼部炎症的 0.05% 環孢菌素眼用乳劑，這是艾爾建 (Allergan) 的 Restasis 的第一個仿製藥。

2021 年 12 月，Abbvie公司獲得了美國 FDA 批准的老花眼治療藥物毛果芸香鹼鹽酸鹽眼用溶液 Vuity。

這份報告提供了什麼

  • 按地區和國家/地區劃分的市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場驅動因素（市場趨勢、制約因素、機遇、威脅、挑戰、投資機會、建議等）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局和趨勢
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 供應鏈趨勢反映了最新的技術進步。

提供免費定制

購買此報告的客戶將免費獲得以下定制之一。

  • 公司簡介
    • 對其他市場參與者（最多 3 個）進行全面分析
    • 主要參與者的 SWOT 分析（最多 3 人）
  • 區域細分
    • 應客戶要求提供主要國家/地區的市場估算、預測和復合年增長率（注意：通過可行性檢查）
  • 競爭基準
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究信息來源
    • 二手研究資源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球眼科藥物市場：按適應症分類

  • 視網膜疾病
    • 糖尿病性黃斑水腫 (DME)
    • 視網膜靜脈阻塞 (RVO)
    • 糖尿病性視網膜病變 (DR)
    • 黃斑變性 (AMD)
  • 青光眼
    • 開角型青光眼
    • 閉角型青光眼
    • 其他
  • 乾眼症
  • 過敏和感染
  • 其他適應症

第 6 章全球眼科藥物市場：按藥物類別分類

  • 抗青光眼
    • α 腎上腺素激動劑
    • β受體阻滯劑
    • 碳酸酐□抑製劑
    • 聯合代理
    • 前列腺素類似物
    • 其他
  • 抗VEGF
  • 抗炎藥
  • 抗感染
  • 其他藥物類別

第 7 章全球眼科藥物市場：按配方分類

  • 半固態
  • 固體
  • 液體

第 8 章全球眼科藥物市場：按分銷渠道

  • 零售店和在線藥店
  • 醫院藥房

第 9 章全球眼科藥物市場：按最終用戶分類

  • 耐心
  • 診斷中心
  • 醫院
  • 眼科

第 10 章全球眼科藥物市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東地區

第11章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals Inc.
  • AbbVie Inc.
  • Santen Pharmaceutical Co. Ltd.
  • Viatris Inc.
  • Novartis AG
  • Eye Pharmaceuticals
  • Roche Valeant
  • Merck & Co.
  • Lpath
  • Alcon Inc.
  • Pfizer Inc.
  • Senju
Product Code: SMRC22646

According to Stratistics MRC, the Global Ophthalmic Disease Therapeutics Market is accounted for $33.56 billion in 2022 and is expected to reach $54.44 billion by 2028 growing at a CAGR of 8.4% during the forecast period. Ophthalmic illness therapeutics comprise medications and therapies used to treat a variety of ocular ailments such as glaucoma, dry eye disease, retinal diseases, and others. The expanding prevalence of these disorders in the population, together with the rising healthcare burden caused by these conditions, is predicted to increase demand for novel medicines and approaches to disease management.

According to the 2021 report published by the Welsh Government, the number of ophthalmic practitioners in Wales increased to 961 in March 2021 from 885 in March 2020.

Market Dynamics:

Driver:

Rising prevalence of ophthalmic conditions

One of the key factors contributing to the growing patient population globally is the increasing prevalence of ophthalmic illnesses such as glaucoma, retinal diseases, dry eye disease, and others among the population. The prevalence of various ocular diseases is shown to be higher in the elderly population. Because of the increasing number of efforts carried out by various healthcare agencies, government entities, and market participants, there is a higher diagnostic and treatment rate among the population.

Restraint:

High cost of biologics

Biologics and biosimilars provide various clinical advantages, including increased effectiveness, safety, and others. However, there are several limits, such as the greater cost of biologics, more out-of-pocket spending, and so on. The higher cost of biologics due to their numerous benefits and varied expenditures involved with their research and approvals is a critical issue restricting the use of these medications in developing nations.

Opportunity:

Increasing clinical trials and pipeline candidates for innovative drugs and therapies

Market players and research organisations are putting more emphasis on developing and launching innovative therapies to treat the illness. The increasing efforts of market participants in R&D activities to develop novel medicines for the treatment of the condition are likely to result in a higher demand for ophthalmic disease therapeutics in the market during the forecast period. The increased focus and vigorous efforts of the market's leading competitors to discover and launch novel medicines to meet the unmet demand for the growing patient population is predicted to raise ophthalmic drug consumption.

Threat:

Lack of awareness

Market expansion is hampered by stringent regulatory frameworks and ambiguous reimbursement practises. Lack of awareness of various ocular problems in rural regions, as well as a lack of health insurance that covers all types of IOLs and contact lenses, are limiting market growth. Vision care has become prohibitively expensive, with many individuals all around the world unable to afford ophthalmic procedures. This is regarded as the key cause of the worldwide ophthalmology pharmaceuticals market's diminishing growth.

Covid-19 Impact

Throughout the projection period, the COVID-19 had a negative impact on market growth. One of the key factors responsible for the market's slower growth during the pandemic is the temporary closure of orthopaedic clinics and a greater concentration of healthcare providers on COVID-19 patients. The lockdown restrictions imposed by government authorities across the regions resulted in the cancellation or postponement of services related with many ocular disorders, as well as a decrease in the number of patient visits to hospitals and clinics. This resulted in a decline in global patient demand for ocular illness medicines.

The anti-VEGF segment is expected to be the largest during the forecast period

The anti-VEGF segment is estimated to have a lucrative growth, due to the rising demand and acceptance of anti-VEGF agents, and the presence of significant market players with extensive product portfolios. Furthermore, the segment's growth is attributed to the great performance of Avastin, LUCENTIS, and others. The current class of anti-VEGF medications is effective but not long-lasting, hence the focus of players on the development of therapeutics with longer action is growing.

The semisolid segment is expected to have the highest CAGR during the forecast period

The semisolid segment is anticipated to witness the fastest CAGR growth during the forecast period, because of the increasing number of product approvals and releases, such as ointment, suspensions, gels, and others. Rising applications of ointment including inflammatory conditions, infections, and dry eye due its increased effectiveness is leading to rising adoption of the semisolid products. Together with this, the rising attention of the leading players on gaining approvals and introducing new products is another factor contributing to the segment's rise.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to rising prevalence of various ocular illnesses combined with higher diagnostic and treatment rate. Furthermore, rising healthcare spending on eye care and eye health in the region, as well as the availability of acceptable reimbursement for various ophthalmic conditions, encourages the adoption of advanced and novel treatments in the region's important countries. A favourable environment for the research and development of numerous revolutionary pharmaceuticals to cure ophthalmic illnesses, as well as the increasing approval of new drugs, are some other factors contributing to the market's growth.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. Increasing biologics and biosimilar launches for the treatment of various eye disorders, increased emphasis on effective ocular condition management, and expanding attempts by market leading players to expand their geographical footprint. The introduction of new products, among other things, is one of the few aspects substantially contributing to market growth. Furthermore, the government's increased investments and advancements in healthcare infrastructure facilities are boosting the market.

Key Players in the market

Some of the key players profiled in the Ophthalmic Disease Therapeutics Market include Bayer AG, F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., AbbVie Inc., Santen Pharmaceutical Co. Ltd., Viatris Inc., Novartis AG, Eye Pharmaceuticals, Roche Valeant, Merck & Co., Lpath, Alcon Inc., Pfizer Inc. and Senju

Key Developments:

In September 2022, Santen Pharmaceutical Co., Ltd. And UBE received approval from the U.S. FDA for Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

In June 2022, F. Hoffmann-La Roche Ltd. Received authorization for Vabysmo, from Health Canada for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).

In March 2022, Novartis AG received approval from the European commission for Beovu, an ophthalmic medicine for the treatment of visual impairment caused due to diabetic macular edema.

In February 2022, Viatris Inc. received approval for Cyclosporine Ophthalmic Emulsion 0.05%, the first generic version of Allergan's Restasis, for the treatment of ocular inflammation.

In December 2021, AbbVie Inc. received approval from the U.S. FDA for Vuity, a pilocarpine Hcl ophthalmic solution for the treatment of presbyopia.

Disease Indications Covered:

  • Retinal Diseases
  • Glaucoma
  • Dry Eye Disease
  • Allergy & Infections
  • Other Disease Indications

Drug Classes Covered:

  • Anti-glaucoma
  • Anti-VEGF
  • Anti-inflammatory
  • Anti-infectives
  • Other Drug Classes

Dosage Forms Covered:

  • Semi-solid
  • Solid
  • Liquid

Distribution Channels Covered:

  • Retail & Online Pharmacies
  • Hospital Pharmacies

End Users Covered:

  • Patients
  • Diagnostic Centres
  • Hospitals
  • Eye Clinics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Ophthalmic Disease Therapeutics Market, By Disease Indication

  • 5.1 Introduction
  • 5.2 Retinal Diseases
    • 5.2.1 Diabetic Macular Edema (DME)
    • 5.2.2 Retinal Vein Occlusion (RVO)
    • 5.2.3 Diabetic Retinopathy (DR)
    • 5.2.4 Macular Degeneration (AMD)
  • 5.3 Glaucoma
    • 5.3.1 Open Angle Glaucoma
    • 5.3.2 Angle Closure Glaucoma
    • 5.3.3 Others
  • 5.4 Dry Eye Disease
  • 5.5 Allergy & Infections
  • 5.6 Other Disease Indications

6 Global Ophthalmic Disease Therapeutics Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Anti-glaucoma
    • 6.2.1 Alpha Adrenergic Agonists
    • 6.2.2 Beta Blockers
    • 6.2.3 Carbonic Anhydrase Inhibitors
    • 6.2.4 Combination Drugs
    • 6.2.5 Prostaglandins Analogs
    • 6.2.6 Others
  • 6.3 Anti-VEGF
  • 6.4 Anti-inflammatory
  • 6.5 Anti-infectives
  • 6.6 Other Drug Classes

7 Global Ophthalmic Disease Therapeutics Market, By Dosage Form

  • 7.1 Introduction
  • 7.2 Semi-solid
  • 7.3 Solid
  • 7.4 Liquid

8 Global Ophthalmic Disease Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail & Online Pharmacies
  • 8.3 Hospital Pharmacies

9 Global Ophthalmic Disease Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Patients
  • 9.3 Diagnostic Centres
  • 9.4 Hospitals
  • 9.5 Eye Clinics

10 Global Ophthalmic Disease Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Bayer AG
  • 12.2 F. Hoffmann-La Roche Ltd.
  • 12.3 Regeneron Pharmaceuticals Inc.
  • 12.4 AbbVie Inc.
  • 12.5 Santen Pharmaceutical Co. Ltd.
  • 12.6 Viatris Inc.
  • 12.7 Novartis AG
  • 12.8 Eye Pharmaceuticals
  • 12.9 Roche Valeant
  • 12.10 Merck & Co.
  • 12.11 Lpath
  • 12.12 Alcon Inc.
  • 12.13 Pfizer Inc.
  • 12.14 Senju

List of Tables

  • Table 1 Global Ophthalmic Disease Therapeutics Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Ophthalmic Disease Therapeutics Market Outlook, By Disease Indication (2020-2028) ($MN)
  • Table 3 Global Ophthalmic Disease Therapeutics Market Outlook, By Retinal Diseases (2020-2028) ($MN)
  • Table 4 Global Ophthalmic Disease Therapeutics Market Outlook, By Diabetic Macular Edema (DME) (2020-2028) ($MN)
  • Table 5 Global Ophthalmic Disease Therapeutics Market Outlook, By Retinal Vein Occlusion (RVO) (2020-2028) ($MN)
  • Table 6 Global Ophthalmic Disease Therapeutics Market Outlook, By Diabetic Retinopathy (DR) (2020-2028) ($MN)
  • Table 7 Global Ophthalmic Disease Therapeutics Market Outlook, By Macular Degeneration (AMD) (2020-2028) ($MN)
  • Table 8 Global Ophthalmic Disease Therapeutics Market Outlook, By Glaucoma (2020-2028) ($MN)
  • Table 9 Global Ophthalmic Disease Therapeutics Market Outlook, By Open Angle Glaucoma (2020-2028) ($MN)
  • Table 10 Global Ophthalmic Disease Therapeutics Market Outlook, By Angle Closure Glaucoma (2020-2028) ($MN)
  • Table 11 Global Ophthalmic Disease Therapeutics Market Outlook, By Others (2020-2028) ($MN)
  • Table 12 Global Ophthalmic Disease Therapeutics Market Outlook, By Dry Eye Disease (2020-2028) ($MN)
  • Table 13 Global Ophthalmic Disease Therapeutics Market Outlook, By Allergy & Infections (2020-2028) ($MN)
  • Table 14 Global Ophthalmic Disease Therapeutics Market Outlook, By Other Disease Indications (2020-2028) ($MN)
  • Table 15 Global Ophthalmic Disease Therapeutics Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 16 Global Ophthalmic Disease Therapeutics Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 17 Global Ophthalmic Disease Therapeutics Market Outlook, By Anti-glaucoma (2020-2028) ($MN)
  • Table 18 Global Ophthalmic Disease Therapeutics Market Outlook, By Alpha Adrenergic Agonists (2020-2028) ($MN)
  • Table 19 Global Ophthalmic Disease Therapeutics Market Outlook, By Beta Blockers (2020-2028) ($MN)
  • Table 20 Global Ophthalmic Disease Therapeutics Market Outlook, By Carbonic Anhydrase Inhibitors (2020-2028) ($MN)
  • Table 21 Global Ophthalmic Disease Therapeutics Market Outlook, By Combination Drugs (2020-2028) ($MN)
  • Table 22 Global Ophthalmic Disease Therapeutics Market Outlook, By Prostaglandins Analogs (2020-2028) ($MN)
  • Table 23 Global Ophthalmic Disease Therapeutics Market Outlook, By Other Drug Classes (2020-2028) ($MN)
  • Table 24 Global Ophthalmic Disease Therapeutics Market Outlook, By Anti-VEGF (2020-2028) ($MN)
  • Table 25 Global Ophthalmic Disease Therapeutics Market Outlook, By Anti-inflammatory (2020-2028) ($MN)
  • Table 26 Global Ophthalmic Disease Therapeutics Market Outlook, By Anti-infectives (2020-2028) ($MN)
  • Table 27 Global Ophthalmic Disease Therapeutics Market Outlook, By Others (2020-2028) ($MN)
  • Table 28 Global Ophthalmic Disease Therapeutics Market Outlook, By Dosage Form (2020-2028) ($MN)
  • Table 29 Global Ophthalmic Disease Therapeutics Market Outlook, By Semi-solid (2020-2028) ($MN)
  • Table 30 Global Ophthalmic Disease Therapeutics Market Outlook, By Solid (2020-2028) ($MN)
  • Table 31 Global Ophthalmic Disease Therapeutics Market Outlook, By Liquid (2020-2028) ($MN)
  • Table 32 Global Ophthalmic Disease Therapeutics Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 33 Global Ophthalmic Disease Therapeutics Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 34 Global Ophthalmic Disease Therapeutics Market Outlook, By Hospital Pharmacies (2020-2028) ($MN)
  • Table 35 Global Ophthalmic Disease Therapeutics Market Outlook, By End User (2020-2028) ($MN)
  • Table 36 Global Ophthalmic Disease Therapeutics Market Outlook, By Patients (2020-2028) ($MN)
  • Table 37 Global Ophthalmic Disease Therapeutics Market Outlook, By Diagnostic Centres (2020-2028) ($MN)
  • Table 38 Global Ophthalmic Disease Therapeutics Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 39 Global Ophthalmic Disease Therapeutics Market Outlook, By Eye Clinics (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.